In addition, it has been demonstrated that the anti-PD-1 drug cemiplimab substantially improved clinical outcomes in advanced NSCLC patients with more than 50% PD-L1 expression, indicating that this drug may be beneficial for NSCLC patients [116]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.